Sutro Biopharma Inc (STRO)

$17.43 +0.80 (4.78%)
Market Cap 141.62M
Revenue (ttm) 62.04M
Net Income (ttm) -227.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -366.63%
Debt to Equity Ratio 0.00
Volume 161,500
Avg Vol 125,104
Day's Range N/A - N/A
Shares Out 8.51M
Stochastic %K 78%
Beta 1.55
Analysts Sell
Price Target $18.33

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 881 6500
Fax: 650 553 9659
Address:
111 Oyster Point Boulevard, South San Francisco, United States
Send_IT_or_stepaside
Send_IT_or_stepaside Feb. 19 at 2:21 PM
$STRO this has done well after the split, haven’t touched it since but good for those who got in after
0 · Reply
topstockalerts
topstockalerts Feb. 18 at 5:13 PM
$STRO Showing strong relative strength versus the market. It’s holding gains while others chop. That’s a bullish sign.
0 · Reply
john714
john714 Feb. 18 at 4:32 PM
$STRO Yeah, baby!
0 · Reply
DailySqueezer
DailySqueezer Feb. 18 at 12:33 PM
$TGL $MTVA $IMG $STRO ×
0 · Reply
PhantomStrike
PhantomStrike Feb. 18 at 7:11 AM
$STRO Sutro Biopharma develops oncology therapies, facing clinical-stage pipeline with binary outcomes and partnership-dependent future [citation:historical].
0 · Reply
___ReversalsTrackerz
___ReversalsTrackerz Feb. 17 at 6:17 PM
$TGL $MTVA $IMG $STRO 7
0 · Reply
DailySqueezer
DailySqueezer Feb. 17 at 1:22 PM
$STRO $XHLD $TLRY $
0 · Reply
john714
john714 Feb. 16 at 2:35 AM
$STRO Time for the next 🦵 up.
0 · Reply
KY3000
KY3000 Feb. 14 at 3:58 PM
$STRO jan1, 251$ mill. Cash was 165$ mill beginning Q3 2025. Its going to be a blowout earnings
0 · Reply
KY3000
KY3000 Feb. 13 at 9:00 PM
$STRO I don’t think it’s coincidence that Astellas has been running for past month, it’s pink sheets, it never moves
0 · Reply
Latest News on STRO
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Feb 10, 2026, 7:00 AM EST - 9 days ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 4:46 PM EST - 4 weeks ago

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Nov 12, 2025, 6:22 PM EST - 3 months ago

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:30 PM EST - 3 months ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Nov 5, 2025, 4:05 PM EST - 3 months ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Nov 3, 2025, 8:00 AM EST - 3 months ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sep 29, 2025, 5:05 PM EDT - 5 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:30 PM EDT - 6 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:31 PM EDT - 10 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025, 4:05 PM EDT - 10 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Apr 28, 2025, 4:05 PM EDT - 10 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 15, 2025, 6:40 PM EDT - 1 year ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 14, 2025, 12:09 PM EDT - 1 year ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 2, 2025, 6:28 PM EST - 1 year ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23, 2024, 12:46 PM EDT - 1 year ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

May 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 5, 2024, 6:31 PM EDT - 2 years ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 6:18 AM EDT - 2 years ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Apr 2, 2024, 1:00 AM EDT - 2 years ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 25, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Jan 4, 2024, 4:05 PM EST - 2 years ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 29, 2023, 4:11 PM EST - 2 years ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 11, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Dec 4, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 21, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Oct 9, 2023, 9:48 AM EDT - 2 years ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sutro BioPharma: Good Stewardship Through Early Trials

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Jun 3, 2023, 4:00 PM EDT - 2 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Send_IT_or_stepaside
Send_IT_or_stepaside Feb. 19 at 2:21 PM
$STRO this has done well after the split, haven’t touched it since but good for those who got in after
0 · Reply
topstockalerts
topstockalerts Feb. 18 at 5:13 PM
$STRO Showing strong relative strength versus the market. It’s holding gains while others chop. That’s a bullish sign.
0 · Reply
john714
john714 Feb. 18 at 4:32 PM
$STRO Yeah, baby!
0 · Reply
DailySqueezer
DailySqueezer Feb. 18 at 12:33 PM
$TGL $MTVA $IMG $STRO ×
0 · Reply
PhantomStrike
PhantomStrike Feb. 18 at 7:11 AM
$STRO Sutro Biopharma develops oncology therapies, facing clinical-stage pipeline with binary outcomes and partnership-dependent future [citation:historical].
0 · Reply
___ReversalsTrackerz
___ReversalsTrackerz Feb. 17 at 6:17 PM
$TGL $MTVA $IMG $STRO 7
0 · Reply
DailySqueezer
DailySqueezer Feb. 17 at 1:22 PM
$STRO $XHLD $TLRY $
0 · Reply
john714
john714 Feb. 16 at 2:35 AM
$STRO Time for the next 🦵 up.
0 · Reply
KY3000
KY3000 Feb. 14 at 3:58 PM
$STRO jan1, 251$ mill. Cash was 165$ mill beginning Q3 2025. Its going to be a blowout earnings
0 · Reply
KY3000
KY3000 Feb. 13 at 9:00 PM
$STRO I don’t think it’s coincidence that Astellas has been running for past month, it’s pink sheets, it never moves
0 · Reply
KY3000
KY3000 Feb. 13 at 3:27 PM
$STRO do I have to say it again, if you believe in vaxcyte, 300$ mill in milestones in the bag
1 · Reply
KY3000
KY3000 Feb. 13 at 3:26 PM
$STRO unless your a big hedge fund, shorts are trapped. Lockup period for 90days, float only 8 mill
0 · Reply
biovaluable
biovaluable Feb. 13 at 9:59 AM
$STRO major boom up! Buying 100,000shares
0 · Reply
KY3000
KY3000 Feb. 12 at 11:18 AM
$STRO time clock start, opus2-3 dosed, vax31 BLA 1stQ2027
0 · Reply
KY3000
KY3000 Feb. 11 at 9:12 PM
$STRO updated corporate presentation. Funded till 2Q 2028, dose 2 happened in 004.
0 · Reply
ibaian
ibaian Feb. 11 at 12:57 AM
$STRO institutional offering, it should be double in few weeks
0 · Reply
OMM22
OMM22 Feb. 10 at 5:11 PM
$STRO wow someone else is on the board its like ghost town and nothing is happening
1 · Reply
KY3000
KY3000 Feb. 10 at 5:09 PM
$STRO this is going to get them to the vaxcyte/blackstone milestone
0 · Reply
KY3000
KY3000 Feb. 10 at 5:08 PM
$STRO I think they got the astellas milestone
1 · Reply
OMM22
OMM22 Feb. 10 at 4:19 PM
$STRO is anyone here on the board anyoneeeeee
0 · Reply
OMM22
OMM22 Feb. 10 at 3:26 PM
$STRO
0 · Reply
HoHoHoHum
HoHoHoHum Feb. 10 at 2:24 PM
$STRO interesting response to offering — they are almost doubling the shares outstanding. But market sees it as bullish! Possibly because they are now fully funded?
0 · Reply